116 Chapter 6 RESULTS Between October 2018 and September 2021, 26 patients were screened. One patient was ineligible because of neutrophil count below the lower limit of normal, and one patient could not enter due to logistic issues. In total, 4 patients were included with advanced NSCLC and 20 patients with early-stage NSCLC. Due to technical issues, [89Zr]Zr-DFO-avelumab PET imaging was only available for 23 patients. [89Zr]Zr-DFO-avelumab dose/timepoint optimization was performed in 13 patients. PD-L1 expression could be determined in 10 (42%) patients. Baseline characteristics are reported in Table 1. Detailed information on all tumor lesions is provided in supplementals. Table 1. Baseline patient characteristics Parameters Patients (n=24) Age in years, median (range) 65.9 53-74 Sex, n(%) Male 12 (50%) ECOG PS, n(%) 0 1 15 9 (63%) (37%) Smoking, n(%) Current Never Former 5 1 18 (21%) (4%) (75%) Histology Adenocarcinoma Squamous cell carcinoma Other* 11 11 2 (46%) (46%) (8%) Clinical disease stage, n(%) Stage I Stage II Stage IIIa Stage IV 11 4 5 4 (45%) (17%) (21%) (17%) PD-L1 status, n(%) PD-L1 CPS <1 PD-L1 CPS 1-49 PD-L1 CPS ≥50 No assessment possible** 6 2 2 14 (25%) (8%) (8%) (19%) * One patient had a small cell lung carcinoma, one other a pleiomorphic carcinoma ** Including all four patients with stage IV disease. Three patients stage I-IIIa disease only had a cytological specimen.
RkJQdWJsaXNoZXIy MTk4NDMw